Figure 1: Mechanism of ISF extraction with Epinostics technology and Visualisation of the Epinostics SAIF-Ex Device.

Figure 2: Animation of the extraction process

Our Science

At the core of Epinostics’ innovation is a transformative technology platform that redefines how biomarkers are sampled from the skin. Our proprietary device, SAIF-EX (Stretch-Activated Interstitial Fluid Extraction), enables non-invasive, painless, and rapid extraction of biomarker-rich interstitial fluid (ISF) directly from the skin—offering a step-change in how we access and analyse physiological information.

Our Technology

Human skin serves as a remarkably effective barrier, preventing harmful environmental agents—such as microbes and pollutants—from entering the body, while also retaining fluids and biomolecules within. This natural barrier, however, also presents a significant challenge for those seeking to sample health-relevant biomarkers non-invasively.

The SAIF-EX device overcomes this barrier by applying gentle, precisely controlled suction to transiently stretch the skin, specifically targeting appendages like hair follicles and sweat glands. This process opens microchannels that allow the selective extraction of interstitial fluid—rich in biomarkers such as cytokines, proteins, peptides, and microbial components. After collection, the skin’s barrier function naturally returns to baseline within 15 minutes. The process is simple, scalable, and safe for all age groups and skin types, and has already been used in over 300 participants with more than 2,000 extractions performed across pilot studies, clinical trials, and device validation programmes.

Figure 2: ISF Extraction volume with SAIF-Ex Device (left). Source of proteins detected in extracted ISF samples (right). Proteomics was performed with two peptide matches.

Table 1: Comparison of technologies used to assess aging compared to Epinostics ISF analysis technology.

Development Pipeline

Epinostics is building a robust pipeline of diagnostic and health monitoring products based on our SAIFi-EX platform. By combining our proprietary extraction technology with advanced data analytics and machine learning, we aim to generate actionable, personalised health data that enhances diagnosis, monitoring, and long-term wellbeing.

We are currently advancing development in three strategic product areas:

  1. EpiAge

    EpiAge targets ageing and longevity by providing biological age assessments through skin-derived biomarkers. Using machine learning models, we analyse molecular signatures of inflammation (inflammaging), cellular senescence, and tissue damage. Our first-in-human pilot study included participants aged 20 to 80 and demonstrated key age-related biomarker trends. The study is now being expanded to cover the full lifespan, from infancy (3 months) through to advanced age.

  2. EpiDerm

    EpiDerm focuses on the diagnosis and progression of atopic dermatitis. Through longitudinal biomarker tracking, including early-life sampling, we are identifying immune and inflammatory signatures that may enable earlier intervention, personalised treatment, and improved disease management. Pilot work is ongoing and spans participants from birth to old age.

  3. EpiAllergy

    EpiAllergy is designed to identify and characterise biomarkers associated with allergic responses, including food and drug-induced allergies. We have completed a pilot study in peanut allergy and are now broadening our scope to include additional allergens and pharmacological triggers, paving the way for targeted diagnostic tools in allergy care.

Figure 3: Development Pipeline of Epinostics diagnostic technologies.